Sector News

Pfizer hires Settleman from Calico to lead cancer R&D

June 6, 2019
Life sciences

Pfizer has hired Jeff Settleman to lead its oncology R&D group. Settleman, who joins from Calico Life Sciences, will lead all cancer programs from discovery to clinical proof of concept.

Today, those activities are overseen by Robert Abraham, who has led the group since 2011. But with Abraham retiring at the end of the year, Settleman is set to take over the responsibilities and become head of Pfizer’s 800-person oncology R&D site in La Jolla, California.

The size of the R&D group is a step up from the one Settleman works with at Calico, a sister company of Google with big plans to treat age-related diseases. Settleman joined Calico in 2015 and has spent the past four years applying his knowledge of molecularly targeted cancer therapies and epigenetic mechanisms of drug resistance to its programs as head of oncology research.

Settleman was one of a clutch of ex-Genentech employees, led by CEO Art Levinson, who found a home at Calico. At Roche’s Genentech, his first industry employer, Settleman worked as senior director of discovery oncology.

Pfizer hopes this experience will support its efforts to claim a growing slice of the cancer market.

“Settleman brings to Pfizer a breadth of experience in fundamental cancer biology, cancer genetics and innovative thinking related to the role of tumor heterogeneity in the development of drug tolerance and resistance. I look forward to seeing his expertise help Pfizer further accelerate potential breakthroughs for people living with cancer,” Pfizer Chief Scientific Officer Mikael Dolsten said in a statement.

Upon joining Pfizer at the start of next month, Settleman will report directly to Dolsten.

Settleman will inherit an organization that had some successes under Abraham. Since 2011, Pfizer has won approval for 10 new oncology drugs and established Ibrance and Xtandi as two of the best-selling cancer treatments. Yet, while sales of those drugs and other cancer medicines are growing quickly, the immuno-oncology boom has to a large extent passed Pfizer by, despite its efforts.

The team tasked with changing that has experienced some churn. Dim­it­ry Nuyten recently stepped down as Pfizer’s immuno-oncology clinical development lead to take up the chief medical officer post at Aduro. And oncology CMO Charles Hugh-Jones jumped ship last year, landing at Allergan.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).